519 related articles for article (PubMed ID: 25763789)
1. Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.
Borad MJ; Gores GJ; Roberts LR
Curr Opin Gastroenterol; 2015 May; 31(3):264-8. PubMed ID: 25763789
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
Graham RP; Barr Fritcher EG; Pestova E; Schulz J; Sitailo LA; Vasmatzis G; Murphy SJ; McWilliams RR; Hart SN; Halling KC; Roberts LR; Gores GJ; Couch FJ; Zhang L; Borad MJ; Kipp BR
Hum Pathol; 2014 Aug; 45(8):1630-8. PubMed ID: 24837095
[TBL] [Abstract][Full Text] [Related]
3. Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas.
Pu X; Ye Q; Cai J; Yang X; Fu Y; Fan X; Wu H; Chen J; Qiu Y; Yue S
Cell Death Dis; 2021 Mar; 12(3):256. PubMed ID: 33692336
[TBL] [Abstract][Full Text] [Related]
4. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
Borad MJ; Champion MD; Egan JB; Liang WS; Fonseca R; Bryce AH; McCullough AE; Barrett MT; Hunt K; Patel MD; Young SW; Collins JM; Silva AC; Condjella RM; Block M; McWilliams RR; Lazaridis KN; Klee EW; Bible KC; Harris P; Oliver GR; Bhavsar JD; Nair AA; Middha S; Asmann Y; Kocher JP; Schahl K; Kipp BR; Barr Fritcher EG; Baker A; Aldrich J; Kurdoglu A; Izatt T; Christoforides A; Cherni I; Nasser S; Reiman R; Phillips L; McDonald J; Adkins J; Mastrian SD; Placek P; Watanabe AT; Lobello J; Han H; Von Hoff D; Craig DW; Stewart AK; Carpten JD
PLoS Genet; 2014 Feb; 10(2):e1004135. PubMed ID: 24550739
[TBL] [Abstract][Full Text] [Related]
5.
Angerilli V; Fornaro L; Pepe F; Rossi SM; Perrone G; Malapelle U; Fassan M
Pathologica; 2023 Apr; 115(2):71-82. PubMed ID: 37017301
[TBL] [Abstract][Full Text] [Related]
6. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
Chong DQ; Zhu AX
Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149
[TBL] [Abstract][Full Text] [Related]
7. Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.
DiPeri TP; Zhao M; Evans KW; Varadarajan K; Moss T; Scott S; Kahle MP; Byrnes CC; Chen H; Lee SS; Halim AB; Hirai H; Wacheck V; Kwong LN; Rodon J; Javle M; Meric-Bernstam F
J Hepatol; 2024 Feb; 80(2):322-334. PubMed ID: 37972659
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma.
Tsujie M; Iwai T; Kubo S; Ura T; Hatano E; Sakai D; Takeda Y; Kaibori M; Kobayashi T; Katanuma A; Katayose Y; Fukase K
Jpn J Clin Oncol; 2021 May; 51(6):911-917. PubMed ID: 33822966
[TBL] [Abstract][Full Text] [Related]
9. Targeting Fibroblast Growth Factor Receptor Pathway: Precision Medicine for Biliary Cancer and Beyond.
Uson Junior PLS; Borad MJ
Semin Liver Dis; 2023 May; 43(2):218-225. PubMed ID: 36882151
[TBL] [Abstract][Full Text] [Related]
10. Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma.
Saborowski A; Vogel A; Segatto O
Trends Cancer; 2022 Feb; 8(2):83-86. PubMed ID: 34840108
[TBL] [Abstract][Full Text] [Related]
11. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
Abou-Alfa GK; Bibeau K; Schultz N; Yaqubie A; Millang B; Ren H; Féliz L
Target Oncol; 2022 Sep; 17(5):517-527. PubMed ID: 36114955
[TBL] [Abstract][Full Text] [Related]
12. Molecular aspects of cholangiocarcinoma.
Kiguchi K
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):371-9. PubMed ID: 24420749
[TBL] [Abstract][Full Text] [Related]
13. Wnt-TCF7-SOX9 axis promotes cholangiocarcinoma proliferation and pemigatinib resistance in a FGF7-FGFR2 autocrine pathway.
Liu Z; Liu J; Chen T; Wang Y; Shi A; Li K; Li X; Qiu B; Zheng L; Zhao L; Shu L; Lian S; Huang S; Zhang Z; Xu Y
Oncogene; 2022 May; 41(20):2885-2896. PubMed ID: 35428876
[TBL] [Abstract][Full Text] [Related]
14. FDFT1/FGFR2 rearrangement: A newly identified anlotinib-sensitive FGFR2 variant in cholangiocarcinoma.
Huang C; Wen Q; Chen J; Zhong H; Xiang X; Xiong J; Deng J
Cancer Treat Res Commun; 2022; 31():100568. PubMed ID: 35477128
[TBL] [Abstract][Full Text] [Related]
15. Highlights of topic "Biochemical and molecular pathological aspects of cholangiocarcinoma".
Murakami Y
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):359-61. PubMed ID: 24840727
[No Abstract] [Full Text] [Related]
16. Potential targeted therapy for liver fluke associated cholangiocarcinoma.
Vaeteewoottacharn K; Seubwai W; Bhudhisawasdi V; Okada S; Wongkham S
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):362-70. PubMed ID: 24408866
[TBL] [Abstract][Full Text] [Related]
17. Specific recognition of an
White BS; Sindiri S; Hill V; Gasmi B; Nah S; Gartner JJ; Prickett TD; Li Y; Gurusamy D; Robbins P; Rosenberg SA; Leko V
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37045473
[TBL] [Abstract][Full Text] [Related]
18. Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?
Braconi C; Roessler S; Kruk B; Lammert F; Krawczyk M; Andersen JB
Liver Int; 2019 May; 39 Suppl 1():32-42. PubMed ID: 30829432
[TBL] [Abstract][Full Text] [Related]
19. Low-level clonal FGFR2 amplification defines a unique molecular subtype of intrahepatic cholangiocarcinoma in a Chinese population.
Pu XH; Ye Q; Yang J; Wu HY; Ding XW; Shi J; Mao L; Fan XS; Chen J; Qiu YD; Huang Q
Hum Pathol; 2018 Jun; 76():100-109. PubMed ID: 29514108
[TBL] [Abstract][Full Text] [Related]
20. [Futibatinib for cholangiocarcinomas with a FGFR2 fusion or rearrangement, locally advanced or metastatic].
Noé C; Edeline J
Bull Cancer; 2023 Oct; 110(10):985-986. PubMed ID: 37500387
[No Abstract] [Full Text] [Related]
[Next] [New Search]